Search details
1.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Future Oncol
; : 1-19, 2024 May 03.
Article
in English
| MEDLINE | ID: mdl-38861289
2.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Future Oncol
; : 1-19, 2024 Jun 12.
Article
in English
| MEDLINE | ID: mdl-38682738
3.
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Eur J Nucl Med Mol Imaging
; 47(11): 2633-2638, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32249345
4.
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
Anticancer Drugs
; 29(7): 705-709, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29846246
5.
Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.
Breast Cancer Res
; 19(1): 106, 2017 Sep 11.
Article
in English
| MEDLINE | ID: mdl-28893303
6.
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
J Urol
; 193(1): 41-7, 2015 Jan.
Article
in English
| MEDLINE | ID: mdl-25046616
7.
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Oncology
; 88(5): 273-80, 2015.
Article
in English
| MEDLINE | ID: mdl-25592399
8.
Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis.
Future Oncol
; 11(23): 3159-66, 2015.
Article
in English
| MEDLINE | ID: mdl-26544922
9.
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.
Ther Adv Urol
; 16: 17562872241244574, 2024.
Article
in English
| MEDLINE | ID: mdl-38638242
10.
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study.
Eur Urol
; 2024 Mar 22.
Article
in English
| MEDLINE | ID: mdl-38521617
11.
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.
Eur Urol Focus
; 2024 Jun 04.
Article
in English
| MEDLINE | ID: mdl-38839505
12.
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).
Tumori
; 110(3): 203-208, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38326240
13.
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.
Front Oncol
; 14: 1307635, 2024.
Article
in English
| MEDLINE | ID: mdl-38410103
14.
Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.
Future Oncol
; 9(6): 831-43, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23718304
15.
Incidence and Survival of Testicular Cancers in a Province in Northern Italy and Their Association with Second Tumors.
Biology (Basel)
; 12(11)2023 Nov 09.
Article
in English
| MEDLINE | ID: mdl-37998008
16.
The Impact of COVID-19 on New Kidney Cancer Diagnosis: Stage and Treatment in Northern Italy.
Int J Environ Res Public Health
; 20(6)2023 03 08.
Article
in English
| MEDLINE | ID: mdl-36981664
17.
[Hormone therapy, cardio-metabolic profile, and cardiotoxicity. Still a dark side of cardio-oncology - Part 2: Prostate cancer]. / Terapia ormonale, assetto cardio-metabolico e cardiotossicità. Il lato ancora oscuro della cardioncologia Parte 2: Tumore della prostata.
G Ital Cardiol (Rome)
; 24(10): 781-791, 2023 Oct.
Article
in Italian
| MEDLINE | ID: mdl-37767830
18.
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Tumori
; 109(1): 129-137, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36447337
19.
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Eur J Cancer
; 187: 174-184, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37167765
20.
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Eur Urol
; 83(1): 82-89, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36216658